MA52667A - Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie - Google Patents

Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie

Info

Publication number
MA52667A
MA52667A MA052667A MA52667A MA52667A MA 52667 A MA52667 A MA 52667A MA 052667 A MA052667 A MA 052667A MA 52667 A MA52667 A MA 52667A MA 52667 A MA52667 A MA 52667A
Authority
MA
Morocco
Prior art keywords
immunotherapy
processes
production
lymphocytes infiltrating
infiltrating tumors
Prior art date
Application number
MA052667A
Other languages
English (en)
Other versions
MA52667B1 (fr
Inventor
James Bender
Seth Wardell
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/940,901 external-priority patent/US10918666B2/en
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of MA52667A publication Critical patent/MA52667A/fr
Publication of MA52667B1 publication Critical patent/MA52667B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/142—Apparatus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
MA52667A 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie MA52667B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/940,901 US10918666B2 (en) 2017-03-29 2018-03-29 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
EP18745741.1A EP3775165B1 (fr) 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
PCT/US2018/040474 WO2019190579A1 (fr) 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie

Publications (2)

Publication Number Publication Date
MA52667A true MA52667A (fr) 2021-02-17
MA52667B1 MA52667B1 (fr) 2024-07-31

Family

ID=63013105

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52667A MA52667B1 (fr) 2018-03-29 2018-06-29 Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie

Country Status (24)

Country Link
EP (2) EP4386080A3 (fr)
KR (2) KR20200138329A (fr)
CN (1) CN112513254A (fr)
AU (2) AU2018415814B2 (fr)
BR (1) BR112020019496A2 (fr)
CA (1) CA3094957A1 (fr)
DK (1) DK3775165T3 (fr)
EA (1) EA202092319A1 (fr)
ES (1) ES2982509T3 (fr)
FI (1) FI3775165T3 (fr)
HR (1) HRP20240850T1 (fr)
HU (1) HUE068082T2 (fr)
IL (1) IL277592A (fr)
LT (1) LT3775165T (fr)
MA (1) MA52667B1 (fr)
MD (1) MD3775165T2 (fr)
MX (1) MX2020010264A (fr)
PL (1) PL3775165T3 (fr)
PT (1) PT3775165T (fr)
RS (1) RS65674B1 (fr)
SG (1) SG11202009170UA (fr)
SI (1) SI3775165T1 (fr)
SM (1) SMT202400287T1 (fr)
WO (1) WO2019190579A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2019236204B2 (en) 2018-03-15 2026-02-26 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
EP4107173A1 (fr) * 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Procédés d'expansion de lymphocytes infiltrant les tumeurs et leur utilisation
EP4143300A1 (fr) 2020-04-28 2023-03-08 Lyell Immunopharma, Inc. Procédés de culture de cellules
EP4253530A4 (fr) 2020-11-25 2024-10-30 Shanghai Juncell Therapeutics Co., Ltd. Milieu de culture de lymphocytes d'infiltration de tumeurs et son application
WO2022130017A2 (fr) * 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Traitement de lymphocytes infiltrant les tumeurs
EP4263807A2 (fr) * 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Traitement de lymphocytes infiltrant les tumeurs
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
KR102666931B1 (ko) * 2021-03-30 2024-05-20 주식회사 네오젠티씨 면역세포 조성물을 생산하는 방법
WO2022263673A1 (fr) * 2021-06-17 2022-12-22 CBio A/S Procédé en plusieurs étapes pour cultiver des lymphocytes infiltrant les tumeurs pour un usage thérapeutique
EP4522728A1 (fr) * 2022-05-11 2025-03-19 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Procédé de préparation et de multiplication d'une population de cellules immunitaires pour la thérapie anticancéreuse, test d?activité biologique pour la reconnaissance des tumeurs, préparation de vaccins biologiques et cible épitope pour les anticorps
WO2025015318A2 (fr) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Vecteurs lentiviraux codant poru des cytokines et leurs utilisations pour la fabrication de lymphocytes infiltrant les tumeurs
WO2025083398A1 (fr) 2023-10-16 2025-04-24 Cell Therapy Catapult Limited Co-culture
CN120888499A (zh) * 2025-09-29 2025-11-04 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) 一种肿瘤浸润淋巴细胞的扩增培养方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
DE69624436T2 (de) 1995-04-08 2003-08-28 Lg Chemical Ltd., Seoul/Soul Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
HUP9904697A3 (en) 1996-10-11 2001-06-28 Bristol Myers Squibb Company P Methods and compositions for immunomodulation
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
WO2004010947A2 (fr) 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Anticorps humanises contre le 4-1bb humain
EP2336293B1 (fr) 2003-10-08 2016-02-10 Wilson Wolf Manufacturing Corporation Procédés et dispositifs pour la culture cellulaire utilisant des matériaux permeables au gaz
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP1894940A1 (fr) 2006-08-28 2008-03-05 Apogenix GmbH Protéines de fusion de la superfamille TNF
CA2692802C (fr) 2007-07-10 2017-05-30 Oliver Hill Proteines de fusion collectines de la superfamille des tnf
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
ES2571879T3 (es) 2008-07-21 2016-05-27 Apogenix Ag Moléculas de una sola cadena de TNFSF
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US8809050B2 (en) 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
HRP20210642T1 (hr) 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
WO2012129201A1 (fr) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procédés de mise en croissance de lymphocytes infiltrant une tumeur dans contenants perméables au gaz
US20140234320A1 (en) 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
CN102816734A (zh) * 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
AU2013262485B2 (en) 2012-05-18 2017-12-14 Wilson Wolf Manufacturing, LLC Improved methods of cell culture for adoptive cell therapy
IL288241B2 (en) 2012-06-11 2023-10-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
AU2013379772B2 (en) 2013-03-01 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive T cells from tumor
JP6560667B2 (ja) 2013-06-24 2019-08-14 ウィルソン ウォルフ マニュファクチャリング コーポレイションＷｉｌｓｏｎ Ｗｏｌｆ Ｍａｎｕｆａｃｔｕｒｉｎｇ Ｃｏｒｐｏｒａｔｉｏｎ 気体透過性細胞培養作業のための閉鎖系装置および方法
EP3686219A1 (fr) 2014-02-04 2020-07-29 Pfizer Inc Combinaison d'un antagoniste de pd -1 et d'un agoniste de 4-1bb pour le traitement du cancer
WO2015157636A1 (fr) * 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Expansion améliorée des lymphocytes infiltrants des tumeurs pour thérapie cellulaire adoptive
EP3838288A1 (fr) 2014-06-11 2021-06-23 polybiocept GmbH Expansion de lymphocytes avec une composition de cytokine pour immunothérapie cellulaire active
FR3040396A1 (fr) * 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي

Also Published As

Publication number Publication date
WO2019190579A1 (fr) 2019-10-03
PT3775165T (pt) 2024-07-17
AU2018415814B2 (en) 2025-08-14
SG11202009170UA (en) 2020-10-29
IL277592A (en) 2020-11-30
SI3775165T1 (sl) 2024-09-30
CN112513254A (zh) 2021-03-16
AU2025256177A1 (en) 2025-11-13
HRP20240850T1 (hr) 2024-09-27
RS65674B1 (sr) 2024-07-31
MX2020010264A (es) 2020-11-06
AU2018415814A1 (en) 2020-10-22
MD3775165T2 (ro) 2024-09-30
EP3775165A1 (fr) 2021-02-17
EP3775165B1 (fr) 2024-03-27
ES2982509T3 (es) 2024-10-16
LT3775165T (lt) 2024-07-10
DK3775165T3 (da) 2024-07-08
KR20250137200A (ko) 2025-09-17
CA3094957A1 (fr) 2019-10-03
HUE068082T2 (hu) 2024-12-28
EP4386080A2 (fr) 2024-06-19
FI3775165T3 (fi) 2024-07-01
BR112020019496A2 (pt) 2021-01-12
MA52667B1 (fr) 2024-07-31
SMT202400287T1 (it) 2024-09-16
PL3775165T3 (pl) 2024-08-19
EA202092319A1 (ru) 2021-03-04
EP4386080A3 (fr) 2024-12-04
KR20200138329A (ko) 2020-12-09

Similar Documents

Publication Publication Date Title
MA52667A (fr) Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie
IL282919A (en) Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
IL269543A (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SI3638698T1 (sl) Protitelesa proti-TMPRSS2 in delci, ki vežejo antigen
EP3664703A4 (fr) Systèmes de neurostimulation et procédés pour affecter la contractilité cardiaque
SI3383916T1 (sl) Protitelesa proti-CD73 in njihove uporabe
EP3397264A4 (fr) Procédés permettant d'améliorer la production et l'isolement de vésicules d'origine cellulaire
WO2016144728A3 (fr) Anticorps anti-lilrb et leur utilisation pour détecter et traiter un cancer
EP3455321A4 (fr) Particules abrasives et leurs procédés de formation
DK3624837T3 (da) Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
EP3443012C0 (fr) Anticorps anti-axl, fragments d'anticorps et leurs immunoconjugués et utilisations associées
EP3455320A4 (fr) Particules abrasives et leurs procédés de formation
EP3436217A4 (fr) Particules abrasives de forme allongée, leurs procédés de réalisation, et articles abrasifs les comprenant
IL272487B (en) Antibodies useful in cancer diagnosis
WO2015153997A3 (fr) Anticorps anti-notch 3 et leurs utilisations
EP3455033A4 (fr) Articles abrasifs et leurs procédés de formation
EP3677913A4 (fr) Procédés de détection de cancers, et réactif de détection
IL266059A (en) Anti-rankl antibodies and their uses
EP3302553A4 (fr) Ligands d'affinité et procédés associés
EP3710603A4 (fr) Procédés pour l'isolation et la récupération de sucres en c5
EP3466970A4 (fr) Anticorps pénétrant dans le cytosol et utilisation associée